Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Skin Cancers
Tumour Sub-type
Melanoma
Tumour stage
Metastatic
Combined Agent(s)
Dacarbazine
Control Arm
Dacarbazine + placebo
Treatment Setting
1st line treatment
Trial Name
CA184-024

Primary Outcome(s)

Primary Outcome(s)
OS
Form(s)
Form 1/Form 2a

Outcome Data

OS Control
9.1 months 8.8% at 5 years
OS Gain
2.1 months 9.4% at 5 years
OS HR
0.69 (0.57-0.84)

Final Score (after adjustments)

Final curative score
A
Preliminary non-curative score
4
Final non-curative Score
4
Long-term plateau in the survival curve
Yes

ChT; chemotherapy; DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PE, point estimate; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.